Astrazeneca Plc(AZN-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low171.42
Day High175.88
Open:175.49
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Guggenheim Keeps Their Buy Rating on AstraZeneca (AZN)
Tipranks
Deutsche Bank Keeps Their Sell Rating on AstraZeneca (AZN)
Tipranks
AstraZeneca (AZN) Receives a Buy from Citi
Tipranks
AstraZeneca Completes Major Russian CKD Diagnosis Study, Setting Stage for Cardiorenal Growth
Tipranks
AstraZeneca Completes Russian Lupus Study, Building Real-World Data Edge
Tipranks
AstraZeneca Sharpens Andexanet Strategy With Completed Phase I Dosing Study
Tipranks
Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)
Tipranks
Goldman Sachs Reaffirms Their Buy Rating on AstraZeneca (AZN)
Tipranks
AstraZeneca (AZN) Gets a Buy from Jefferies
Tipranks
J.P. Morgan Keeps Their Buy Rating on AstraZeneca (AZN)
Tipranks
AstraZeneca’s Wainua misses primary goal in major ATTR-CM heart trial
Tipranks
AstraZeneca Halts Russian Real-World Selumetinib Study: What It Means for AZN Investors
Zacks Investment Research
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study
AstraZeneca's Stock Drops on Wainua's Setback in ATTR-CM Study
Tipranks
AstraZeneca (AZN) Gets a Buy from Citi
Zacks Investment Research
MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?
MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?
Zacks Investment Research
Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
Pfizer or AstraZeneca: Which Stock Offers Better Long-Term Potential?
Tipranks
AstraZeneca (AZN) Receives a Buy from Bernstein
Zacks Investment Research
Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?
Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?
Newswire.ca
As AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the Models

Profile

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.